On November 10, 2025, the U.S. Department of Health and Human Services and the FDA announced they were starting to remove the broad “black box” warnings from menopause hormone therapy products. For more than two decades, those warnings had shaped how many women and clinicians viewed estrogen. The announcement made headlines, and many women reasonably asked: does this mean hormone therapy is safe now?
The short answer is that the change adds nuance, not a guarantee. Understanding what moved, and what did not, will help you have a better conversation about your own options.
Why the warning existed
The boxed warnings were added in the early 2000s after the Women’s Health Initiative (WHI) study reported increased risks of breast cancer, heart disease, stroke, and blood clots in women taking certain hormone therapy. The findings led many women to stop treatment and many clinicians to avoid prescribing it.
Later analysis pointed out that the average WHI participant was in her early 60s, more than a decade past the typical start of menopause, and that the study tested specific products. Researchers have since found that age and time since menopause strongly influence the balance of benefits and risks.
What the FDA said is changing
According to the FDA and HHS announcement, the agency is working with manufacturers to update labeling for menopausal hormone therapy. The changes include removing boxed-warning references to the risks of cardiovascular disease, breast cancer, and probable dementia. The agency also said it would add information indicating that starting hormone therapy within 10 years of menopause onset, or before age 60, may offer benefits.
The FDA said it is not seeking to remove the boxed warning about endometrial cancer for systemic estrogen-alone products. That risk is why women who have a uterus generally take a progestogen along with estrogen.
What did not change
A label is a summary of risk, not a removal of risk. The underlying research did not disappear. Hormone therapy is still not recommended for everyone. Conditions that typically require careful evaluation, or may rule treatment out, include:
- A history of breast cancer or other hormone-sensitive cancers
- Previous blood clots, stroke, or heart attack
- Active liver disease
- Unexplained vaginal bleeding
Your age, time since menopause, family history, blood pressure, and personal preferences still matter.
A note about compounded and pellet products
The labeling change applies to FDA-approved hormone therapy products, which carry FDA labels. Compounded hormones, including many pellet and custom cream preparations, are not FDA-approved products and do not carry the same FDA labeling. The removal of the boxed warning should not be read as a new FDA endorsement of compounded therapy. If your provider recommends a compounded product, ask why it is preferred over an approved option for you and how dosing will be monitored.
Questions worth bringing to your appointment
- Based on my age and time since menopause, how do benefits and risks compare for me?
- Which symptoms are we treating, and how will we measure improvement?
- Is an FDA-approved product appropriate, or is there a reason to consider compounded therapy?
- Do I need a progestogen because I have a uterus?
- What screening, such as mammograms or blood pressure checks, should continue?
- How often will we review whether to continue?
Symptoms worth discussing
Hot flashes, night sweats, sleep problems, mood changes, vaginal dryness, and changes in libido are common reasons women seek care. They are also symptoms that can overlap with thyroid problems, medication side effects, or other conditions, which is why evaluation matters.
How Harmony approaches hormone care
Harmony Med Spa in Sarasota offers hormone evaluations and bioidentical hormone therapy, including pellet therapy, with exams and follow-up care. A consultation should review your symptoms, history, lab work, and goals before any recommendation. If the news prompted you to revisit hormone therapy, that is a good reason to ask questions. The label change opens the door to a more individualized conversation; it does not replace one.
Frequently asked questions
Did the FDA say hormone therapy is completely safe?
No. The FDA began removing boxed warnings about cardiovascular disease, breast cancer, and probable dementia, but risks still exist and individual evaluation is still needed.
Is the endometrial cancer warning gone too?
No. The FDA said it is not seeking to remove the boxed warning about endometrial cancer for systemic estrogen-alone products.
Does the change apply to hormone pellets?
The labeling change applies to FDA-approved products. Compounded preparations, including many pellets, are not FDA-approved and are not covered by that labeling.
Does timing matter when starting hormone therapy?
Yes. The updated labeling is expected to note potential benefits when therapy starts within 10 years of menopause onset or before age 60.
Who still should not take hormone therapy?
People with certain cancers, prior clots, stroke, heart attack, liver disease, or unexplained bleeding need careful evaluation and may not be candidates.
Should I restart hormones I stopped years ago?
Discuss it with a provider. Your age, time since menopause, and health history have changed, so the decision should be made fresh.
Sources and further reading
FDA/HHS: HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy (Nov 10, 2025): https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy-1
Harmony hormone replacement therapy: https://www.harmonymedspafl.com/hormone-replacement-therapy
Continue exploring
Personalized care in Sarasota
Ready to discuss your options?
A consultation connects the information in this guide to your health history, goals, timeline, and budget.
Talk through hormone-therapy options